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Objective: To determine the most common reasons and surgical approaches for corneal graft surgery at the Kensington Eye
Institute (KEI), University of Toronto.
Design: Retrospective cross-sectional study.
Participants: A total of 229 consecutive corneal transplants performed at the KEI.
Methods: Demographic, clinical, and pathological data on all 2012 and 2013 corneal transplants were collected.
Results: The mean age for corneal transplants was 65  16 years; 39% were full-thickness penetrating keratoplasties (PK) and
61% were partial-thickness. Graft failure (30%), infection (18%), and keratoconus (17%) were the leading indications for PK.
Fuchs’ dystrophy (40%) and bullous keratopathy (24%) were main causes for partial-thickness procedures. Among partial-
thickness approaches, Descemet’s stripping automated endothelial keratoplasty (DSAEK), deep anterior lamellar keratoplasty
(DALK), and Descemet’s membrane endothelial keratoplasty (DMEK) procedures accounted for 68%, 16%, and 16%,
respectively. Fuchs’ dystrophy (40%) and bullous keratopathy (33%) were the most common indications for DSAEK. Keratoconus
(57%) and corneal scarring (35%) were the most common indications for DALK, whereas Fuchs’ dystrophy (82%) accounted for
most DMEK procedures. The most common reasons for all corneal grafts were Fuchs’ dystrophy (25%), bullous keratopathy
(21%), graft failure (17%), and keratoconus (12%).
Conclusions: Almost two-thirds of all corneal transplant procedures at the University of Toronto are partial thickness procedures.
A failed graft was found to be the most common indication for full-thickness transplants. Fuchs’ dystrophy was the most common
indication for a partial-thickness approach, most often treated by DSAEK. Longitudinal data are needed to determine whether
partial-thickness surgeries will improve graft survival and reduce the need for regraft.& 2016 The Autho
of Canadian Ophth
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ISSN 0008-4182/1Recent technological advances have led to the adoption of
partial-thickness procedures as an alternative to full-
thickness replacement of the cornea, with surgical choices
guided by the location of the pathology. Selective replace-
ment of the endothelium for diseases such as Fuchs’
dystrophy can be achieved by procedures such as Desce-
met’s stripping automated endothelial keratoplasty
(DSAEK) and Descemet’s membrane endothelial kerato-
plasty (DMEK). The anterior stromal layers can be
targeted as in deep anterior lamellar keratoplasty (DALK)
for diseases such as keratoconus and corneal scarring.
Many studies of corneal transplant surgery are derived
from data spanning 2000–2010, a period of evolution and
adoption of partial-thickness corneal transplants in addi-
tion to surgeon learning. During that period, signiﬁcant
increases in the number of partial-thickness corneal trans-
plants were reported from Scotland,1 New Zealand,2
China,3 Colombia,4 the United Kingdom,5 Iran,6 and
Canada.7–9 DSAEK leads in the treatment of corneal
endothelial disease, as does DALK for anterior cornea
opacity.rs. Published by Elsevier Inc. on behalf
almological Society. All rights reserved.
0.1016/j.jcjo.2016.07.005
6Although corneal procedures have matured over the
years, information regarding current practice patterns from
major academic centres in Canada regarding the type of
and indications for corneal grafts are limited. Corneal
transplant surgery at the University of Toronto was only
recently centralized from major teaching hospitals in the
city to the Kensington Eye Institute (KEI), an academic
health centre providing ambulatory surgical care. This
provided a unique opportunity to evaluate the types of
procedures performed and their indications from multiple
academic centres and faculty. Here we report mainly 2013
data on full- and partial-thickness corneal transplantation,
their indications, and patient demographics from the
largest single academic centre for corneal graft surgery in
Canada.METHODS
Institutional Research Ethics Board approval (REB No.
13-225) was obtained from St. Michael’s Hospital, Tor-
onto, Canada, on October 30, 2013. This researchCAN J OPHTHALMOL—VOL. ], NO. ], ] 2016 1










39 (89) 59  16.6 1:1
Partial-thickness
transplant
61 (140) 68  15.2 2:3
DSAEK 41 (95) 73  11.1 1:2
DALK 10 (23) 47  16.0 2:1
DMEK 10 (22) 71  11.4 1:2
DSAEK, Descemet’s stripping endothelial keratoplasty; DALK, deep anterior lamellar
keratoplasty; DMEK, Descemet’s membrane endothelial keratoplasty.
Corneal transplants at the university of toronto—Le et al.adhered to the tenets of the Declaration of Helsinki.
A retrospective review was conducted, and included
clinical and pathological records of all adult corneal
transplants performed at the KEI surgical center of the
University of Toronto, from November 6, 2013 (date of
ﬁrst corneal transplant surgery at KEI), to December 31,
2013. Data were obtained from the University of Toronto
Ophthalmic Pathology Laboratory and included the type
of corneal surgery performed, clinical/pathological indica-
tion, and demographic information, including age and sex.
All cases with conﬁrmed clinical and pathological diag-
noses were included. The data were categorized according
to the type of procedure performed, separating full-
thickness transplants from partial-thickness transplants.
Data on partial-thickness transplants were further
categorized as DSAEK, DMEK, or DALK. Each proce-
dure type was assessed according to its disease indications
and the age and sex of patients. Three cases of DALK were
converted to penetrating keratoplasties (PK). Cases in
which clinical indications were not provided and patho-
logical results showed corneal endothelial cell loss without
characteristic ﬁndings of Fuchs’ dystrophy were termed
“non-Fuchs’ dystrophy,” and cases of congenital hereditary
endothelial dystrophy were also included here. A category
of “others” included least common indications: granular
dystrophy, central cloudy dystrophy of Francois, lattice
dystrophy, pterygium, thick Descemet’s membrane, irido-
corneal endothelial syndrome, trauma, neurotrophic ker-
atopathy, corneal ulcer, toxic anterior segment syndrome,
and uveitis.RESULTS
Two hundred and twenty-nine corneal transplants were
performed from November 2012 to December 2013
(patients’ mean age 65  16 years). Of these, 89 (39%)
were full-thickness corneal transplants, and 140 (61%)
were partial-thickness corneal transplants (Fig. 1A).
Patients undergoing full-thickness transplants (59  17
years) were signiﬁcantly younger compared with thoseFig. 1—Of corneal transplant surgeries performed at University
and 140 (61%) were partial-thickness (A). Most partial-thickness
keratoplasty (DSAEK) (68%), followed by deep anterior lame
endothelial keratoplasty (DMEK) (16%) (B).
2 CAN J OPHTHALMOL—VOL. ], NO. ], ] 2016who had partial-thickness transplants (68  15 years)
(p o 0.0001). Partial-thickness procedures performed
were DSAEK (68%), DALK (16%), and DMEK (16%)
(Fig. 1B). Of the partial-thickness patients, the average age
was 73  11 years for DSAEK, 47  16 years for DALK,
and 71  11 years for DMEK (Table 1).
Full-thickness transplants were performed for most
cases of infection (89%), graft failure (68%), other (see
methods) (57%), keratoconus (54%), and corneal scarring
(47%). Partial-thickness transplants were performed for
most cases of non-Fuchs’ dystrophy (100%), Fuchs’ dys-
trophy (98%), bullous keratopathy (71%), and corneal
scarring (53%) (Fig. 2).
The most common indication for full-thickness trans-
plant was graft failure (30%), followed by infection (18%)
and keratoconus (17%) (Fig. 3A). The most common
indication for partial-thickness transplant was Fuchs’ dys-
trophy (40%), followed by bullous keratopathy (24%) and
both keratoconus and graft failure (9%). Among the
partial-thickness procedures, keratoconus (57%) and cor-
neal scarring (35%) were the most common indications
for DALK procedures (Fig. 3B). Fuchs’ dystrophy (40%)
and bullous keratopathy (33%) were the most common
indications for DSAEK (Fig. 3C). Most DMEK proce-
dures (82%) were performed for Fuchs’ dystrophy
(Fig. 3D).
The most common indications for all corneal graft
surgery were Fuchs’ dystrophy (25%), bullous keratopathyof Toronto 2012–2013 (n ¼ 229), 89 (39%) were full-thickness
procedures were Descemet’s stripping automated endothelial
llar keratoplasty (DALK) (16%), and Descemet’s membrane
Fig. 2—Full-thickness transplants were performed most com-
monly for infection, graft failure, scar, and keratoconus.
Partial-thickness transplants were performed most com-
monly for non-Fuchs’ dystrophy (100%), Fuchs’ (98%), and
bullous keratopathy cases (71%).
Corneal transplants at the university of toronto—Le et al.(21%), and graft failure (17%) (Table 2). Among Fuchs’
dystrophy patients, 67% were treated with DSAEK, 31%
by DMEK, and 2% by PK (Fig. 4A). Among patients with
graft failure, 68% of patients underwent PK and 32%
underwent DSAEK (Fig. 4B). Bullous keratopathy
patients were mostly treated by DSAEK (65%), followed
by PK (29%) and DMEK (6%) (Fig. 4C).Fig. 3—When penetrating keratoplasty (PK) was performed, the
and keratoconus (17%) (A). For deep anterior lamellar keratopla
corneal scarring (35%) (B). For Descemet’s stripping automate
Fuchs’ dystrophy (40%) and bullous keratopathy (33%) (C). For
cases were Fuchs’ dystrophy (82%) (D).Patients with Fuchs’ dystrophy (69.9  9.4 years),
bullous keratopathy (75.2  8.5 years), graft failure (66.8
 16.6 years), infection (64.7  14.1 years), and non-
Fuchs’ dystrophy (63.8  16.8 years) were older than
those treated for keratoconus (42.0  14.5 years) and
corneal scarring (55.4  14.0 years) (Table 2).DISCUSSION
Recent centralization of corneal transplant surgery at
the University of Toronto to the KEI provided an
opportunity to evaluate types and indications of corneal
graft surgery across multiple academic teaching hospitals
and faculty. We found that approximately 61% of trans-
plants performed in 2013 were partial-thickness grafts.
Growing trends in Ontario from 2007 to 2010 have been
reported,7 and advancements in partial-thickness proce-
dures and outcomes, technology, and surgeon experience
over the past decade likely play some role. Partial-thickness
procedures have become attractive alternatives to full-
thickness procedures with evidence of improved visual
outcomes, earlier visual recovery, and comparable graft
survival rates of 94% and 90% for partial-thickness and
full-thickness, respectively.10–17 Full-thickness transplant
recovery time is typically 1 year, whereas recovery rates for
partial-thickness transplants may be 4–6 weeks.11,18,19
Among the partial-thickness procedures, a growing
trend for the use of DSAEK in the surgical treatment ofleading indications were graft failure (30%), infection (18%),
sty (DALK), leading indications were keratoconus (57%) and
d endothelial keratoplasty (DSAEK), leading indications were
Descemet’s membrane endothelial keratoplasty (DMEK), most
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Mean Age  SD
(years)
Fuchs’ dystrophy 24.9 (57) 69.9  9.4
Bullous keratopathy 20.9 (48) 75.2  8.5
Graft failure 17.4 (40) 66.8  16.6
Keratoconus 12.2 (28) 42.0  14.5
Infection 7.9 (18) 64.7  14.1
Corneal scarring 7.4 (17) 55.4  14.0
Other 6.1 (14) 71.3  16.0
Non-Fuchs’ Dystrophy 3.1 (7) 63.8  16.8
Corneal transplants at the university of toronto—Le et al.corneal endothelial disease has been reported.1,4 Our study
showed that more DSAEK than DMEK procedures were
performed for Fuchs’ dystrophy (67% vs 31%). As
DMEK was relatively new at the time, it is possible that
fewer surgeons were performing the procedure. Among the
endothelial keratoplasty procedures (DSAEK and
DMEK), DSAEK continues to be the more popular
procedure. DMEK is known to be technically challenging
with higher risk of the thin donor tissue dislocating or
tearing.18 Continuing improvements to the DMEK pro-
cedure may increase its frequency of use in treating corneal
endothelial diseases.20
In our patients with corneal scarring, 47% were treated
with PK and 47% were treated with DALK. Similar
proportions were found for keratoconus patients. For both
of these conditions, PK was performed equally as or more
often. Studies have reported increased frequency of DALK
between 2001 and 2010.8,21 DALK has been found to
have visual and refractive outcomes comparable to PK;
however, data on long-term graft survival are varia-
ble.16,22,23 Use of one technique over the other is depend-
ent on the disease severity and presence of risk factors, and
experts agree that DALK is the preferred treatment for
keratoconus unless other factors such as deep scarring are
involved.24
We found that more partial-thickness transplants,
speciﬁcally DSAEK and DMEK, were performed in older
patients compared with full-thickness transplants. Full-
thickness transplants were performed for corneal scarringFig. 4—Procedures performed for Fuchs’ dystrophy (A), bullou
automated endothelial keratoplasty (DSAEK) was the most com
whereas penetrating keratoplasty (PK) was the most common f
4 CAN J OPHTHALMOL—VOL. ], NO. ], ] 2016and infection, which may occur across a spectrum of ages.
The increasing frequency of partial-thickness techniques
performed for corneal endothelial diseases like Fuchs’
dystrophy helps to explain the older demographic, given
that Fuchs’ dystrophy is not typically symptomatic until
the sixth decade of life. Among partial-thickness transplant
patients, DSAEK and DMEK patients’ had a higher age
(70s) compared with DALK patients, with the average age
found to be 47.4  16 years (Table 2). DALK was
indicated commonly to treat keratoconus and consistent
with expected onset in the 20s, taking 10 to 20 years to
progress to a surgical stage.25
Although published data regarding current corneal
transplant indications and types in major centres are
limited, data from the 2000 to 2010 period from Scot-
land,1 New Zealand,2 Australia,22 the United Kingdom,5
Iran,6 and Germany26 found that keratoconus was a
leading indication, and as high as 41% of total trans-
plants. Hungary19 and Colombia4 reported bullous kerat-
opathy to be the most common cause. In China, the
leading cause was infectious keratitis,3 whereas in Canada,
pseudophakic corneal edema was dominant from 2000 to
2009.21 These differences reﬂect diverse demographics
and local pathologies and may change with future treat-
ment advances.
Our study found Fuchs’ dystrophy as a leading indica-
tion for corneal transplant (25%), and Canadian data from
2010 to 2012 reported Fuchs’ dystrophy emerging as a
major cause.8,9,27 Improvements in cataract surgical tech-
niques have likely reduced the cases of pseudophakic
corneal edema, coincident with the widespread adoption
of partial-thickness procedures for Fuchs’ dystrophy.
Bullous keratopathy (21%), graft failure (17%), and
keratoconus (12%) were all important indications for
corneal grafts.
Most graft failures were treated with PK (68%). The
cause of graft failure is an important consideration in
patients undergoing surgery, and as endothelial cell loss is
a common reason for graft failure, partial-thickness
procedures may be more beneﬁcial.28–30 Studies have
shown that after an initial failed PK, repeat PK ands keratopathy (B), and graft failure (C). Descemet’s stripping
mon procedure in Fuchs’ dystrophy and bullous keratopathy,
or graft failure.
Corneal transplants at the university of toronto—Le et al.DSAEK have similar graft survival rates and visual out-
comes.31–34 DSAEK has been shown to result in less
endothelial cell loss compared with PK.11 Long-term
graft survival data show that endothelial keratoplasty
procedures may be superior in regrafts, with 5-year
survival rates of 86% for endothelial keratoplasty and
51% for PK.30,32
Attempts to reduce graft failure rates by increasing
graft size may reduce endothelial cell loss but lead to
irregularity of graft surface, among other problems.35 In
cases of graft failure due to neovascularization, inﬂam-
mation, or infection, many layers may be affected. For
these challenging patients, partial-thickness procedures
are less likely to be sufﬁcient. Despite PK as the treat-
ment choice for these graft failure patients, a high-risk
graft bed contributes to high rates of failure in subse-
quent transplant procedures.36 Future improved ability
to categorize the graft bed by risk and medical inter-
ventions may help address cases at higher risk of fail-
ure.37,38 Long-term survival studies of partial-thickness
procedures are needed to determine whether this
approach will affect the need for regrafting.
Current practice at the KEI, University of Toronto,
indicates that almost two-thirds of all corneal trans-
plants performed are partial-thickness transplants. Fuchs’
dystrophy, bullous keratopathy, and graft failure are the
most common reasons for corneal transplantation. Most
Fuchs’ dystrophy and bullous keratopathy are treated
with partial-thickness procedures. Full-thickness trans-
plants remain the preferred choice for graft failure.
Longitudinal data and further research are needed to
determine whether longer graft survival and higher
success rates with partial-thickness transplants will
reduce the demand for corneal transplants due to graft
failure.REFERENCES
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